Inhibrx to Present at Major Scientific Conferences in 2026
Inhibrx to Present at Major Scientific Conferences in 2026
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, has announced its participation in several significant upcoming scientific conferences in 2026. The company will present pivotal data relating to their innovative therapeutic candidates aimed at treating various cancers, including head and neck squamous cell carcinoma and conventional chondrosarcoma.
Upcoming Conferences
2026 European Society for Medical Oncology (ESMO) Congress
- - Date: October 25, 2026
- - Location: Madrid, Spain
- - Presentation Title: _HexAgon-HN: Phase 2/3 Study of Ordastobart in Combination with Pembrolizumab for High PD-L1 Recurrent/Metastatic Head and Neck Cancer_
- - Format: Oral Presentation
- - Lead Author: Jong Chul Park
- - Time: 8:30 AM - 10:00 AM CET
This study focuses on analyzing the efficacy of the hexavalent OX40 agonist ordastobart (INBRX-106) when used in conjunction with pembrolizumab, emphasizing its use as a first-line treatment option.
2026 Musculoskeletal Tumor Society (MSTS) Annual Meeting
- - Date: October 29, 2026
- - Location: Miami, Florida
- - Presentation Title: _Ozekibart in Conventional Chondrosarcoma: An Analysis of Secondary Efficacy Endpoints from the Phase 2 ChonDRAgon Study_
- - Format: Oral Presentation
- - Lead Author: Robin Jones
- - Time: 2:50 PM - 3:40 PM EST
The focus here is on Ozekibart (INBRX-109), showcasing its potential efficacy in treating conventional chondrosarcoma through a rigorous analysis of data obtained during clinical trials.
2026 Connective Tissue Oncology Society (CTOS) Annual Meeting
- - Date: November 19-20, 2026
- - Location: Seoul, South Korea
In two key presentations, Inhibrx will discuss the performance of Ozekibart (INBRX-109) within subgroup analyses related to conventional chondrosarcoma, as well as a phase 1/2 study examining its combination with chemotherapy for adolescents and adults suffering from Ewing Sarcoma.
1. Subgroup Analysis of Ozekibart
- Date/Time: November 20, 2026, 11:00 AM - 12:30 PM KST
- Lead Author: Sant Chawla
2. Phase 1/2 Study of Ozekibart Combined with Irinotecan and Temozolomide
- Date/Time: November 19, 2026, 5:30 PM - 6:30 PM KST
- Lead Author: Varun Monga
Presentations and posters will be accessible through Inhibrx’s investor relations section on their website.
About Inhibrx Biosciences
Inhibrx Biosciences is dedicated to advancing its pipeline of novel biotherapeutics by utilizing advanced protein engineering techniques. Established as a wholly-owned subsidiary of Inhibrx, Inc. in January 2024, the company aims to tackle complex disease mechanisms with innovative treatments such as Ozekibart (INBRX-109) and Ordastobart (INBRX-106).
The ongoing development of these candidates showcases Inhibrx’s commitment to unlocking new therapeutic avenues in oncology, particularly in challenging areas where effective treatment options are limited.
For further information about the company's studies and upcoming presentations, visit Inhibrx's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.